Piramal Pharma LTD has a strong presence of inhaled anesthetics in the United States and emerging markets, plans to expand and promote growth by expanding the pipeline of the injection agent. The chairman told Mint in an interview.
On January 22, the company launched the chlorpromajin hydrochloride, an injection agent used to treat mental illness in the United States. This is the latest injection from Piramal Cratical Care, a generic arm of the company’s complex hospital.
In 2024, a new sulfate zinc in injection, following the treatment of muscle atrophy side sclerosis (ALS), and in 2023 in injections in injection of pantoprazol sodium injection and doxys cyclin. I did.
“Inhalation anesthetics, injections can be injected pains and inverted cavity products, but it’s a common business. We already have a good market share, so from these complex injections to be added to portfolio. I expect more growth, “said Pilamal. Not only the license of the development project, but also developed and released.
Complex hospital generic
Pharma Company reports the growth of 14 % of the complex hospital generic business in the third quarter of the year. £It was mainly driven by the 654 crawl, its large -scale sales volume of the inhaled anesthesia portfolio. The company is the largest seller of Sebofluran, an inhaled anesthetic drug in the US market, which has more than 40 % market share, and has more than 70 % market share in the United States in Baclofen, a muscle relaxant.
According to a report from the ICICI retail survey, the Sebofluran accounts for about 80 % of the global inhalation anesthesia market, releasing relatively small greenhouse gases. The paper also states that there is a faster appearance and recovery than other drugs.
Despite the price pressure, the generic business of the hospital’s hospital has a limited number of niches with limited channels that are different from competition, and is an advantageous segment that provides 25 to 30 % margins. JM Financial said in a last month’s report. With the addition of Sevofullan’s abilities in India, the release of injection products, securities companies are expecting 11 % of the segments between FY24-27.
Piramal Pharma sold the domestic formulation business to Abbot in 2010 for $ 3.8 billion, and then strengthened the critical care resource business with important acquisitions. The non -competitive agreement with Abbott expired in 2018.
Tide in the United States
Piramal Pharma’s contract development, manufacturing and manufacturing (CDMO) business increased 18 % year -on -year in the first nine months of FY25 due to the continuous traction in salary commercial production and general API business. 。
Last year, the company, which invested $ 80 million at a Lexington factory in Lexington in the United States, expects President Donald Trump’s uncertainty about the future movement of President Donald Trump.
“We have to wait and see what they are planning, but for those who want to manufacture in the United States, we have a available capacity. In the United States There is a very powerful manufacturing network, “Pilamaru said.
Piramal anticipates that the CDMO business will be the largest margin driver of the company soon.
Piramal Pharma posted the results of the third quarter on Tuesday and increased 12.54 % year -on -year to make a profit. £2,204.22 crawl. Profit has decreased by 63.6 % £3.68 crawls. EBITDA increased by 6 % year -on -year £350 crawls, the company reported 16 % of EBITDA margins. The company estimates that 25 % EBITDA margins will reach $ 2 billion.
Pilamaru pharmaceutical stocks decreased by 0.25 % £BSE 239.10 am at 11:28 am. Stocks are about 72 % in the past year.
